# Chronic Myeloid Leukemia

## Introduction

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm defined by the Philadelphia chromosome, a reciprocal translocation between chromosomes 9 and 22, t(9;22)(q34.1;q11.2), which generates the BCR-ABL1 fusion oncoprotein. The incidence is approximately 1 to 2 per 100,000 per year, with a median age at diagnosis of 55 to 60 years. CML represents the paradigm of molecularly targeted therapy in oncology: the introduction of tyrosine kinase inhibitors has transformed what was once a uniformly fatal disease into a chronic condition with near-normal life expectancy for most patients who achieve and maintain adequate molecular responses. The natural history of CML proceeds through three recognizable phases: chronic phase, accelerated phase, and blast crisis.

## Molecular Biology

### BCR-ABL1 Fusion

The Philadelphia chromosome is created by a reciprocal translocation that juxtaposes the BCR gene on chromosome 22 with the ABL1 gene on chromosome 9, producing the BCR-ABL1 fusion gene on the derivative chromosome 22. The resulting BCR-ABL1 protein is a constitutively active tyrosine kinase that drives leukemogenesis through the activation of multiple downstream signaling pathways, including RAS/MAPK, JAK/STAT, and PI3K/AKT, promoting proliferation, survival, and genomic instability.

Three major fusion transcript variants are recognized based on the breakpoint within BCR. The p210 transcript (e13a2 or e14a2) is the classic CML transcript, present in approximately 95% of CML cases. The p190 transcript (e1a2) is the predominant fusion in Philadelphia-positive ALL and is only rarely found in CML, where it is associated with a more aggressive phenotype. The p230 transcript (e19a2) is rare and is associated with a neutrophilic CML variant. The ABL1 kinase domain is the target of all approved tyrosine kinase inhibitors, and mutations within this domain represent the principal mechanism of TKI resistance.

### Disease Progression

The progression of CML from chronic phase through accelerated phase to blast crisis reflects the sequential acquisition of additional genetic abnormalities. Additional chromosomal abnormalities (ACAs) that herald disease progression include trisomy 8, isochromosome 17q, a second Philadelphia chromosome (double Ph+), and trisomy 19. At the molecular level, progression is driven by the accumulation of mutations in tumor suppressor genes (TP53), transcription factors (RUNX1, IKZF1), epigenetic regulators (ASXL1), and RAS pathway components. Blast crisis is classified as either myeloid (accounting for approximately two-thirds of cases) or lymphoid (one-third), a distinction that carries important therapeutic implications, as lymphoid blast crisis may respond to ALL-type chemotherapy combined with a TKI.

## Diagnosis and Staging

### Chronic Phase

The typical presentation of chronic phase CML includes marked leukocytosis, often with a white blood cell count exceeding 100,000 per microliter, accompanied by a left shift that characteristically demonstrates a "myelocyte bulge," in which myelocytes are present in numbers exceeding metamyelocytes. Basophilia and eosinophilia are common accompanying findings. Splenomegaly, which may be massive, is a frequent physical finding. The peripheral blood smear reveals the entire spectrum of myeloid maturation, from myeloblasts (constituting fewer than 10% of cells) through promyelocytes, myelocytes, metamyelocytes, bands, and segmented neutrophils. The bone marrow is markedly hypercellular with granulocytic hyperplasia, and megakaryocytes are characteristically small and hypolobated, described as "dwarf megakaryocytes."

The diagnosis is confirmed by the identification of the Philadelphia chromosome on conventional cytogenetics, BCR-ABL1 fusion by FISH, and quantification of the BCR-ABL1 transcript by RT-qPCR, which serves as the basis for ongoing molecular monitoring.

### Accelerated Phase (WHO 5th Edition)

The WHO 5th Edition defines accelerated phase by the presence of 10 to 19% blasts in the blood or bone marrow, peripheral basophils constituting 20% or more of the differential, persistent thrombocytopenia below 100,000 per microliter unrelated to therapy, or clonal cytogenetic evolution with the acquisition of additional chromosomal abnormalities in Philadelphia-positive cells. The ELN and ICC criteria differ slightly, with some systems considering certain high-risk additional cytogenetic abnormalities as "warning" features rather than defining accelerated phase.

### Blast Crisis

Blast crisis is defined by 20% or more blasts in the blood or bone marrow, or the presence of extramedullary blast proliferation. Myeloid blast crisis is characterized by blasts expressing MPO, CD13, and CD33, and is treated with a TKI combined with AML-type induction chemotherapy. Lymphoid blast crisis features blasts expressing TdT, CD19, and CD10, and is treated with a TKI combined with ALL-type induction chemotherapy. Lymphoid blast crisis carries a somewhat better prognosis than myeloid blast crisis.

<image>A three-panel diagram showing CML disease phases (chronic, accelerated, blast crisis) arranged left to right with increasing severity. For each phase, show: a representative peripheral blood smear image (CP: orderly myeloid maturation with myelocyte bulge; AP: increased blasts and basophils; BC: sheet of blasts). Below each smear, list the diagnostic criteria (blast %, basophil %, cytogenetic features). At the bottom, show a molecular progression timeline with accumulating genetic hits (BCR-ABL1 alone in CP, then additional abnormalities like trisomy 8, +Ph, isochromosome 17q, and eventually TP53/RUNX1 mutations in BC). Include a survival curve showing the dramatic difference in outcomes between phases. Medical pathology education style.</image>

## Treatment - First-Line TKI Therapy

### Imatinib (Gleevec)

Imatinib was the first tyrosine kinase inhibitor developed for CML and targets the ATP-binding site of the BCR-ABL1 kinase in a competitive fashion. The landmark IRIS trial (2003), which compared imatinib to the prior standard of interferon-alpha plus cytarabine, demonstrated a complete cytogenetic response rate of 82% versus 35%, fundamentally transforming CML management. The standard dose for chronic phase CML is 400 mg daily. Long-term follow-up data demonstrate a 10-year overall survival of approximately 85%, with the annual rate of disease progression declining over time to approximately 1 to 1.5% per year. The availability of generic imatinib has significantly reduced the cost of CML treatment.

### Dasatinib (Sprycel)

Dasatinib is a second-generation TKI that is approximately 325-fold more potent than imatinib in vitro and functions as a dual SRC/ABL inhibitor. The DASISION trial compared dasatinib at 100 mg daily against imatinib at 400 mg daily as first-line therapy and demonstrated faster and deeper molecular responses with dasatinib. Dasatinib is active against most imatinib-resistant BCR-ABL1 kinase domain mutations with the notable exception of the T315I gatekeeper mutation. Its unique toxicity profile includes pleural effusions, which occur in approximately 28% of patients and may require dose reduction or drug discontinuation, and rarely pulmonary arterial hypertension, a serious complication that mandates permanent discontinuation. Dasatinib requires gastric acid for absorption, and concomitant use of proton pump inhibitors should be avoided.

### Nilotinib (Tasigna)

Nilotinib is a second-generation TKI that is approximately 30-fold more potent than imatinib and demonstrates greater selectivity for the BCR-ABL1 kinase. The ENESTnd trial demonstrated faster achievement of complete cytogenetic response and major molecular response compared to imatinib when nilotinib was administered at 300 mg twice daily. Like dasatinib, nilotinib is active against most imatinib-resistant mutations except T315I. The most clinically significant toxicity is cardiovascular, with a cumulative 5-year incidence of peripheral arterial occlusive disease, coronary artery disease, and cerebrovascular events of 7 to 13%. Additional toxicities include QTc prolongation, hyperglycemia, and pancreatitis. The drug must be taken on an empty stomach (no food for 2 hours before or 1 hour after dosing). Nilotinib should be avoided in patients with significant pre-existing cardiovascular risk factors.

### Bosutinib (Bosulif)

Bosutinib is a second-generation dual SRC/ABL inhibitor. The BFORE trial demonstrated a higher rate of major molecular response at 12 months compared to imatinib (47.2% versus 36.9%) when bosutinib was administered at 400 mg daily. It is active against most imatinib-resistant mutations except T315I. The principal toxicities include diarrhea (occurring in approximately 70% of patients, though mostly grade 1-2 and self-limited), hepatotoxicity requiring monitoring of liver function tests, and rash. Bosutinib may be a preferred choice for patients with cardiovascular risk factors, given its lower cardiovascular toxicity profile compared to nilotinib.

### Choosing First-Line TKI

The selection of a first-line TKI requires consideration of both disease-related and patient-related factors. Imatinib offers the advantages of extensive long-term safety data, well-established tolerability, generic availability, and excellent long-term outcomes, though it achieves responses more slowly. Second-generation TKIs (dasatinib, nilotinib, bosutinib) achieve faster and deeper molecular responses, potentially increasing eligibility for treatment-free remission, but each carries unique toxicity concerns that must be weighed against these benefits. Patient-specific factors that guide selection include cardiovascular risk (favoring avoidance of nilotinib; consider imatinib or bosutinib), pulmonary disease (favoring avoidance of dasatinib), gastrointestinal issues (favoring avoidance of bosutinib), and the desire for deep molecular response or treatment-free remission candidacy (favoring a second-generation TKI).

| TKI | Generation | Dose (CP-CML) | Potency vs Imatinib | Key Trial | Unique Toxicities | Avoid If |
|---|---|---|---|---|---|---|
| Imatinib | 1st | 400 mg daily | 1x (reference) | IRIS | Edema, muscle cramps, GI upset | -- (well-tolerated; generic available) |
| Dasatinib | 2nd | 100 mg daily | 325x | DASISION | Pleural effusions (28%), PAH (rare) | Pulmonary disease |
| Nilotinib | 2nd | 300 mg BID | 30x | ENESTnd | Arterial occlusive events (7-13% at 5 yr), QTc prolongation, hyperglycemia | Cardiovascular risk factors |
| Bosutinib | 2nd | 400 mg daily | ~30x | BFORE | Diarrhea (70%), hepatotoxicity | Severe GI disease |
| Ponatinib | 3rd | 45 mg → 15 mg (OPTIC) | Active vs T315I | OPTIC | Arterial thrombosis (dose-dependent), pancreatitis | -- (reserved for resistance/T315I) |
| Asciminib | STAMP | 40 mg BID (or 200 mg BID for T315I) | Allosteric (different site) | ASCEMBL | Favorable profile; pancreatic enzyme elevations | -- (3rd+ line or T315I) |

## Monitoring and Response Milestones

### Molecular Monitoring (BCR-ABL1 IS%)

Molecular monitoring by RT-qPCR for BCR-ABL1 transcripts, reported on the International Scale (IS), is the cornerstone of treatment response assessment. At 3 months, BCR-ABL1 should be 10% or less on the International Scale; a level above 10% at this timepoint is a warning sign that warrants consideration of TKI switch and assessment of treatment adherence. At 6 months, BCR-ABL1 should be 1% or less (equivalent to complete cytogenetic response); a level above 10% constitutes treatment failure requiring a TKI switch. At 12 months, BCR-ABL1 should be 0.1% or less, corresponding to major molecular response (MMR or MR3); a level above 1% constitutes treatment failure. Deep molecular responses are defined as MR4 (BCR-ABL1 0.01% or less), MR4.5 (0.0032% or less), and MR5 (0.001% or less), and are required for consideration of treatment-free remission. Monitoring should be performed by RT-qPCR every 3 months, with results reported on the standardized International Scale.

| Timepoint | Optimal Response | Warning | Failure (Requires TKI Switch) |
|---|---|---|---|
| 3 months | BCR-ABL1 ≤10% IS | BCR-ABL1 >10% IS | -- |
| 6 months | BCR-ABL1 ≤1% IS (CCyR) | BCR-ABL1 1-10% IS | BCR-ABL1 >10% IS |
| 12 months | BCR-ABL1 ≤0.1% IS (MMR) | BCR-ABL1 0.1-1% IS | BCR-ABL1 >1% IS |
| Any time | BCR-ABL1 ≤0.1% IS (MMR maintained) | Loss of MMR; mutations | Loss of CHR; loss of CCyR; mutations; new CCA/Ph+ |

### Definitions

Complete cytogenetic response (CCyR) is defined as 0% Philadelphia-positive metaphases on conventional cytogenetics. Major molecular response (MMR/MR3) is defined as BCR-ABL1 at or below 0.1% on the International Scale. Treatment failure at any milestone requires a TKI switch, and ABL1 kinase domain mutation analysis should be performed to guide the selection of the next agent. A "warning" response warrants closer monitoring and consideration of a switch but does not mandate immediate action.

## Resistance Management

### BCR-ABL1 Kinase Domain Mutations

ABL1 kinase domain mutation analysis should be performed whenever treatment failure or warning signs are identified. The T315I "gatekeeper" mutation is the most clinically significant, as it confers resistance to all first- and second-generation TKIs and responds only to ponatinib or asciminib. Other commonly encountered resistance mutations include Y253H and E255K/V (sensitive to nilotinib), F317L and V299L (resistant to dasatinib). Compound mutations, in which two mutations are present on the same BCR-ABL1 molecule, are highly resistant and may require ponatinib or transplant.

### Ponatinib (Iclusig)

Ponatinib is a third-generation TKI with activity against T315I and virtually all other BCR-ABL1 kinase domain mutations. The OPTIC trial established a dose-optimization strategy: ponatinib is initiated at 45 mg daily and reduced to 15 mg daily once BCR-ABL1 falls to 1% or below, balancing efficacy with the dose-dependent risk of arterial thrombotic events. Additional toxicities include hypertension and pancreatitis.

### Asciminib (Scemblix)

Asciminib represents a first-in-class mechanism as a STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor. Unlike all other approved TKIs, asciminib binds to the myristoyl pocket of ABL1 through an allosteric mechanism rather than competing at the ATP-binding site. The ASCEMBL trial demonstrated superior major molecular response rates with asciminib at 40 mg twice daily compared to bosutinib in patients who had received two or more prior TKIs (25.5% versus 13.2% at 24 weeks). Asciminib is also active against the T315I mutation when administered at 200 mg twice daily. Its safety profile is favorable, with no significant cardiovascular signal identified to date. Asciminib is currently approved for chronic phase CML after two or more prior TKIs and for T315I-mutated CML.

## Treatment-Free Remission (TFR)

### Concept and Eligibility

Treatment-free remission refers to the discontinuation of TKI therapy in patients who have achieved and sustained a deep molecular response, with the goal of maintaining durable molecular remission off therapy. The eligibility criteria, as defined by NCCN and ELN guidelines, include at least 3 years of total TKI therapy, at least 2 years of sustained MR4 (BCR-ABL1 at or below 0.01%), chronic phase disease only with no prior history of accelerated phase or blast crisis, and access to reliable molecular monitoring with RT-qPCR sensitivity of at least MR4.5.

### Key Trials

The STIM trial was among the first to demonstrate the feasibility of TKI discontinuation, with 40% of patients maintaining major molecular response after imatinib cessation at 12 months. The larger EURO-SKI trial showed that 52% of patients maintained MMR at 6 months, with the majority of relapses occurring within the first 6 months of discontinuation. Deeper and longer duration of deep molecular response before discontinuation correlate with higher probability of successful TFR. TKI withdrawal syndrome, manifesting as musculoskeletal pain, occurs in up to 30% of patients who discontinue therapy and is usually self-limited, though its mechanism remains unclear.

### Monitoring During TFR

The monitoring schedule during TFR is intensive: monthly BCR-ABL1 PCR testing for the first 6 months, bimonthly for months 7 through 12, and quarterly thereafter. Loss of major molecular response (BCR-ABL1 above 0.1%) requires immediate TKI restart. Virtually all patients who restart TKI therapy after loss of MMR regain their molecular response. Confirmed loss of MMR constitutes TFR failure, and TKI therapy should be resumed indefinitely.

<image>A treatment-free remission (TFR) decision pathway for CML. Start with "Stable Deep Molecular Response on TKI." Show eligibility criteria in a checklist box: ≥3 years TKI, ≥2 years MR4 or deeper, CP-CML only, reliable monitoring access. If eligible, show "Discontinue TKI" with monitoring schedule: monthly PCR for 6 months, bimonthly for 6 months, then quarterly. Branch at molecular monitoring: "Maintained MMR" → continue monitoring (TFR success, approximately 50%). "Loss of MMR (BCR-ABL1 >0.1%)" → restart TKI immediately → "Regain DMR" (>95% re-respond). Include a graph showing the typical molecular kinetics: initial BCR-ABL1 fluctuation after TKI stop, with some patients maintaining undetectable levels and others showing molecular recurrence requiring TKI restart. Clean clinical pathway format with timeline axis.</image>

## Key Clinical Pearls
- BCR-ABL1 >10% IS at 3 months is a critical early warning sign; failure to achieve this milestone warrants consideration of TKI switch and adherence assessment
- Adherence is the most common cause of suboptimal response; imatinib adherence <80% is associated with significantly lower CCyR and MMR rates
- T315I mutation renders all first- and second-generation TKIs ineffective; ponatinib and asciminib are the only options (short of transplant)
- Nilotinib cardiovascular toxicity is cumulative and dose-dependent; assess cardiovascular risk before selection and monitor aggressively
- TFR is achievable in ~50% of patients with sustained deep molecular response; it should be offered to eligible patients with reliable monitoring infrastructure
- Allogeneic HSCT remains the only curative option for TKI-refractory disease or blast crisis; it is rarely needed in the TKI era

## References
1. Hochhaus A, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia (IRIS 10-year update). N Engl J Med. 2017;376(10):917-927.
2. Cortes JE, et al. Asciminib versus bosutinib in chronic myeloid leukemia (ASCEMBL). N Engl J Med. 2021;386(10):902-914.
3. Saussele S, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI). Lancet Oncol. 2018;19(6):747-757.
4. Hochhaus A, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-984.
5. Cortes JE, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia (OPTIC). Blood. 2021;138(21):2042-2050.